Ignite Creation Date:
2024-05-06 @ 6:45 PM
Last Modification Date:
2024-10-26 @ 2:54 PM
Study NCT ID:
NCT05774340
Status:
RECRUITING
Last Update Posted:
2023-12-15
First Post:
2023-03-06
Brief Title:
A Study of CM326 in Subjects With Moderate to Severe Asthma
Sponsor:
CSPC ZhongQi Pharmaceutical Technology Co Ltd
Organization:
CSPC ZhongQi Pharmaceutical Technology Co Ltd
Study Overview
Official Title:
A Randomized Double-Blind Placebo-Controlled Phase Ⅱ Clinical Study to Evaluate the Efficacy and Safety of CM326 in Subjects With Moderate to Severe Asthma
Status:
RECRUITING
Status Verified Date:
2023-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is a multi-center randomized double-blind placebo-controlled Phase Ⅱ clinical study to evaluate the efficacy safety PK characteristics PD effects and immunogenicity of CM326 in subjects with moderate to severe asthma
The study consists of three periods including an up to 4-week screening period a 52-week treatment period and a 12-week safety follow-up period
The study consists of three periods including an up to 4-week screening period a 52-week treatment period and a 12-week safety follow-up period
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None